New combo shows promise for tough bile duct cancer in early trial

NCT ID NCT07530445

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Apr 17, 2026 · Last updated Jun 13, 2026 · Updated 11 times

Summary

This study tests a new combination of drugs (iparomlimab, tuvonralimab, chemotherapy, and lenvatinib) as a second-line treatment for people with advanced bile duct cancer that has worsened after first-line therapy. The goal is to see if this approach can help control the cancer and improve survival. About 40 participants will be enrolled at a single center in China.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SECOND-LINE THERAPY FOR UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Zhiqiang Wang, guangzhou, Other (Non U.S.) 510000 Recruiting
RECRUITING

Guangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SECOND-LINE THERAPY FOR UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER SECOND-LINE THERAPY FOR UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER